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Abstract 
 
The in vitro screening for trypanocidal activity against T.b. rhodesiense of an in-
house library of 62 compounds [i.e. alkane, diphenyl and aza-alkane bisguanidines and 
bis(2-aminoimidazolines)] which were chosen for their structural similarity to the 
trypanocidal agents synthalin (1,10-decanediguanidine) and 4,4’-
diguanidinodiphenylmethane, and the polyamine N1-(3-amino-propyl)-propane-1,3-
diamine respectively, is reported. The original synthetic procedure for the preparation of 
21 of these compounds is also reported.  
Most compounds displayed low micromolar anti-trypanosomal activity with five of 
them presenting a nanomolar inhibitory action on the parasite: 1,9-nonanediguanidine 
(1c), 1,12-dodecanediguanidine (1d), 4,4’-bis[1,3-di(tert-butoxycarbonyl)-2-
imidazolidinylimino]diphenylamine (28a), 4,4'-bis(4,5-dihydro-1H-2-
imidazolylamino)diphenylamine (28b), 4,4’-diguanidinodiphenylamine (32b) and 1,4-
bis[4-(4,5-dihydro-1H-2-imidazolylamino)phenyl]piperazine (41b). Those molecules, 
which showed an excellent in vitro activity as well as high selectivity for the parasite 
[e.g. 1c (IC50 = 49 nM; SI > 5294), 28b (IC50 = 69 nM; SI = 3072), 32b (IC50 = 22 nM; 
SI = 29.5), 41b (IC50 = 118 nM; SI = 881)], represent new anti-trypanosomal lead 
compounds. 
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Introduction 
Sleeping sickness (Human African Trypanosomiasis, HAT) is caused by two sub-
species of African trypanosomes, Trypanosoma brucei gambiense and T. brucei 
rhodesiense, responsible for the chronic and acute form of the disease respectively.1 
Only four drugs are licensed for the treatment of HAT 2 (DFMO, suramin, pentamidine 
and melarsoprol) although other drugs such as berenil (usually used against animal 
trypanosomiasis) or the nitrofuran nifurtimox (registered for use against Chagas’ 
disease) have also proved useful in some limited cases. The actual situation of re-
emergence of sleeping sickness in sub-Saharan Africa, with prevalence of an estimated 
500,000 infected individuals,3 and the drawbacks of the current HAT chemotherapy 
(e.g. toxicity, increasing resistance, parenteral mode of administration, price) make the 
search for new trypanocidal drugs urgently needed.4  
Many diamidine, diguanidine and polyamine compounds have been investigated 
for their antitrypanosomal activity as far as 65 years ago,5-11 giving rise, for instance, to 
the aromatic diamidine drug pentamidine12 which is still used nowadays for the 
treatment of early stage T.b. gambiense infections. However, this drug is unable to cross 
the blood-brain barrier in sufficient quantity to treat late-stage cases of HAT.13 Other 
aromatic diamidines such as propamidine or berenil are used as antiprotozoal 
chemotherapy in cattle and the trypanocidal activity of dicationic derivatives related to 
pentamidine have been reported as well (Figure 1).9,14,15 The polyamine metabolic 
pathway of trypanosomatid parasites has attracted much attention as drug target for the 
last 15 years.16 This research led to the synthesis and evaluation of many polyamine 
analogues as chemotherapeutic agents against parasitic infections,17-20 being the 
trypanothione reductase a particularly targeted enzyme (Figure 1).21-23 
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There is a clear lack of research investment in the field of tropical diseases in 
comparison to the number of affected population.24,25 Thus, a reasonable approach for 
the discovery of new anti-trypanosomal lead compounds at a lesser cost is the screening 
for anti-parasitic activity of already available molecules. Hence, a rapid look at the 
structure of the polyamine, diguanidine and diamidine compounds reported as 
antiprotozoal agents in the literature put into evidence the potential as possible 
trypanocides of a series of bisguanidine and bis(2-aminoimidazoline) compounds 
previously synthesized in our laboratory for other purposes.26-28 Moreover, some of the 
alkanediguanidine [1,8-octanediguanidine (1b),29 1,12-dodecanediguanidine (1d),6,30,31 
bis(guanidinopropyl)amine (6a)32] and diphenyl compounds [4,4’-
diguanidinodiphenylmethane (31b), 4,4’-diguanidinodiphenylsulfone (33b)]8 available 
in our in-house library had been previously reported for their use as either trypanocide, 
microbicides or fungicides. Of particular interest was the recent report on N,N’-bis(4-
amidinophenyl)piperazine (Figure 1) which proved to be a very effective anti-
trypanosomal agent in vivo.15 Hence, in the search for new HAT chemotherapy, we 
decided to carry out an in vitro screening against the parasite T. brucei rhodesiense of a 
total of 62 compounds (Tables 1-5) taken from our in-house library and structurally 
related to the trypanocidal agents synthalin (1,10-decanediguanidine) and 4,4’-
diguanidinodiphenylmethane (31b), and the polyamine N1-(3-amino-propyl)-propane-
1,3-diamine respectively. We also describe here the original synthesis of 21 molecules 
which had not been previously reported.  
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Results  
Chemistry 
Synthesis of the aliphatic compounds 1a-d, 2a-d, 3b-d, 4a-b, 5a, 5b, 5d, 6a-b, 7, 8, 
9, 11-13, 21-24 (Tables 1, 2, 3 and 4) as well as the diphenyl derivatives 27a-33a, 27b-
33b and 34 (Table 5, entry 1-15) has been previously reported by us.26,27,28  
Synthesis of the 3-aza-1,6-hexanediamine derivatives (Scheme 1). Guanylation 
of 3-aza-1,6-hexanediamine with an excess of DCC in CH3CN afforded a mixture of the 
di-substituted  dicyclohexylguanidine derivative 5c and the tri-substituted compound 
17. These products were separated by preparative reverse phase HPLC.  
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3-Aza-1,6-hexane diamine selectively protected on the primary amino group with 
benzylcyanoformate28,33 (5d) was used as starting material for the preparation of the 3-
substituted derivatives 8-10, 14-16, 18-20 and 25-26 (Scheme 1). Alkylation of 5d with 
bromoethylbenzene or 2-bromoethanol yielded 8 (83 %) and 20 (69 %) respectively. 
Hydrogenolysis of 8 with 10% Pd-C/1M HCl/MeOH afforded the amine 9 which was 
subsequently refluxed with S-methylisothiouronium sulphate in CH3CN, yielding the 
bis-guanidine 10 (46 %). When 5d was treated with chloroacetaldehyde in excess under 
reductive conditions (NaBH(OAc)3/AcOH/CH3CN) at room temperature, the 
chloroethyl derivative 19 (35 %) was obtained together with the acetate side-product 18 
(16 %). In this reaction, the nucleophilic substitution of chloroacetaldehyde (or 2-
chloroethanol derived from the reduction in situ of chloroacetaldehyde) by the 
secondary amine 5d, leading to a hydroxyethyl intermediate that can react with AcOH 
present in the reaction medium, is a potential competitive reaction. Working at low 
temperature (0 ºC) was unfavourable to the competitive nucleophilic substitution and 19 
could be obtained in 69 % in these conditions. 
An interesting feature was the methylation of 5d with formaldehyde under 
reductive conditions (NaBH3CN/CH3CN).
34 Three main products were isolated 
depending on the pH of the reaction. Working in basic medium (i.e. pH > 7, no AcOH 
added) yielded the methylated product 14 (51 %) whereas acidic medium afforded both 
five and six-member ring aminals 25 and 26 respectively. Structural characterisation of 
both derivatives was carried out by 1D (1H, 13C) and 2D-NMR experiments (i.e. HSQC, 
HMBC). A characteristic difference between the 1H NMR spectra of 25 and 26 were the 
aminal methylene protons which appeared as a singlet of two protons for the six-
member ring derivative 26 whereas two singlets (separated by 14.8 Hz) were observed 
for the five member ring counterpart 25. This might account for the observation of two 
 8 
conformers of the acyl derivative 25.35 Study of the 3JH-C coupling constants between 
the aminal methylene protons and their neighbours allowed to characterising both 
compounds.  
 
25
N NCbzCbzHN N NCbz NHCbz
26
Cbz
H
N
H
N N
H
Cbz
5c: R = Gua-C6H11; R' = H
17: R = R' = Gua-C6H11 =
R
H
N N N
H
R
14: R = Cbz
15: R = H
16: R =
Me
H2N
H
N NH2
a
c
d
f
e
Scheme 1. Reagents and conditions. (a) PhCH2CO2CN (2 equiv.), CH2Cl2; (b) HCHO, NaBH3CN, AcOH (pH<7), MeCN; (c) HCHO, 
NaBH3CN, MeCN (pH>7); (d) H2, Pd-C 10%, MeOH, HCl 1M; (e) 2-methylmercapto-4,5-dihydroimidazole iodide, MeOH, reflux; (f) DCC, 
MeCN, rt; (g) 2-bromoethanol, MeCN, reflux; (h) chloroacetaldehyde (4 equiv.), NaBH(OAc)3, AcOH, MeCN, rt; (i) bromoethylbenzene, 
K2CO3, CH3CN, reflux; (j) S-methylisothiouronium sulfate, CH3CN, reflux.
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Synthesis of the diphenyl derivatives (Scheme 2). Guanidines 31c and 32c were 
obtained by reaction of an ether solution of N-(2,2’-diethoxyethyl)carbodiimide 
(prepared from BrCN and aminoacetaldehyde-diethylacetal)36 with 4,4’-
diaminodiphenylamine and 4,4’-diaminodiphenymethane in the presence of CH3SO3H, 
respectively. Preparation of the 2-aminoimidazole 35 was carried out by base-catalysed 
cyclisation of the guanidine precursor 31c following the methodology of Munk et al..36 
In this reaction, two cyclisation products could potentially form: (1H-imidazol-2-yl)-
aryl-amine (“endocyclic” amino group) and 1-aryl-1H-imidazol-2-ylamine (“exocyclic” 
amino group). 1H NMR spectrum of 35 showed a unique broad singlet for 4-H and 5-H 
imidazol protons at 6.76 ppm whereas decoupled 13C NMR spectrum showed a unique 
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signal for both 4- and 5- imidazole carbons indicating the magnetic equivalence of these 
atoms. These data demonstrated that the expected product 35 with the endocyclic amino 
group was obtained (e.g. if the isomer with exocyclic amino group were obtained, a 
typical AB system would be observed for the 4- and 5-H imidazol protons).   
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Scheme 2. Reagents and conditions. (a) N-(2,2'-diethoxyethyl)carbodiimide (2.2 equiv.); 
CH3SO3H (2 equiv.); EtOH, reflux, 23h; (b) 1) 6M HCl, rt, 3h, 2) 10% NaOH, rt, 1h; (c) 
NBS, t-BuOOH, CCl4, reflux; (d) tri-n-pentylphosphine (4 equiv.); PhMe, reflux, 24h.
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Compound 37 has been previously described37 as a B2 bradykinin receptor 
antagonist. The reported procedure was quite lengthy so we designed a three steps 
synthesis starting from 4,4’-dimethylbenzophenone. Radicalar bromination of 4,4’-
dimethylbenzophenone with NBS/t-BuOOH/CCl4 allowed the formation of the 
dibromo-derivative compound 36 which was isolated by crystallisation from the 
reaction mixture (22 % yield). The low yield obtained could be explained by the 
formation of a mixture of mono- and poly-halogenated derivatives (e.g. three spots were 
observed by TLC of the crude reaction mixture).38 The bis-phosphonium compound 37 
was obtained by nucleophilic substitution of the bromine atoms of 36 with an excess of 
tri-n-pentylphosphine in refluxing toluene. Tri-n-pentylphosphine was prepared by a 
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modification of the procedure described by Davies et al..39 The reaction of an excess of 
bromopentane Grignard’s reagent with phosphorous trichloride working at -78 ºC40 
afforded the tri-n-pentylphosphine which was purified by fractional distillation. 
Synthetic approach for the preparation of the piperazine-based bisguanidine and 
bis(2-aminoimidazoline) compounds is depicted in scheme 3. Aromatic nucleophilic 
substitution of 1-fluoro-4-nitrobenzene with the commercially available 1-(4-nitro-
phenyl)-piperazine in DMSO at 100 ºC afforded 38.41 Nitro groups were reduced by 
catalytic hydrogenation (10 % Pd-C/HCl/MeOH) affording the amine 3942. Introduction 
of the Boc-protected guanidine and imidazoline moieties (compounds 40a and 41a 
respectively) was carried out in good yield with N,N’-di(tert-butoxycarbonyl)thiourea43 
and N,N’-di(tert-butoxycarbonyl)imidazoline-2-thione26 respectively. Removal of the 
Boc-protecting groups was accomplished by treatment with TFA, affording 40b and 
41b as their trifluoroacetate salts. 
 F
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Scheme 3. Reagents and conditions. (a) DMSO, 100 oC, 60h (73%); (b) H2 (40 Psi), 10% Pd-C, HCl, 
MeOH, rt (59%); (c) N,N'-bis(tert-butoxycarbonyl)-thiourea (2.2 equiv.), HgCl2, Et3N, DMF, 0 oC then 
rt (73%); (d) TFA, CH2Cl2 (88%); (e) N,N'-bis(tert-butoxycarbonyl)imidazoline-2-thione (2.2 equiv.), 
HgCl2, Et3N, DMF, 0 oC then rt (66%).
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Biological results. In vitro anti-trypanosomal activity 
The results of the determination of anti-trypanosomal activity against bloodstream 
form trypomastigotes of T.b. rhodesisense (strain STIB 900) are reported in Tables 1 to 
5. All compounds displayed dose-dependant activities against T.b. rhodesiense, with 
IC50 ranging from 0.022 µM to 113 µM, and were selective for the parasite. Eight 
aliphatic (1b-d, 2b-d, 13 and 17) and 12 diphenyl derivatives (27b, 28a-b, 31b-c, 32a-c, 
34, 37, 40b and 41b) showed an IC50 < 1 µM. Among the latter, five compounds had an 
IC50 in the nanomolar range (1c, 1d, 28a, 28b and 32b) with a selectivity index (SI) 
ranging from 13 (1d) to more than 5000 (1c). 
 
Alkane and aza-alkane derivatives (Tables 1 and 2). The most potent compound 
within the alkane (Table 1) and aza-alkane (Table 2) derivative series was 1,9-
nonanediguanidine  (1c) with IC50 = 49 nM and a remarkable selectivity for the parasite 
(SI > 5294).  In these series, the guanidinium cation gave in general more active 
compounds (about 2 to 4-fold) than the 2-aminoimidazolinium counterpart (compare 
1a-d / 2a-d). This was also true for the aza-alkane series (Table 2, 5a/5b and 6a/6b). 
Increasing the chain length of the methylene spacer (n = 6, 8, 9, 12) between either 
guanidinium or 2-aminoimidazolinium cations tended to increase the activity with the 
following order: n = 6 < n = 8 (ca 30-fold) < n = 9 ~ n = 12 (Table 1). Regarding the 
selectivity, the nine-methylene spacer (1c and 2c) gave the best SI (5294 and 71) in both 
series. Noteworthy was the greater activity displayed by the dicationic derivatives 1b-d 
and 2b-d with respect to their monocationic counterparts (Table 1). This behaviour was 
also observed for the aza-alkane compound 6b which was 3.5-fold more active than 7 
(Table 2).  
 
 12
Tables 1 around here44 
 
Introduction of an unsubstituted nitrogen atom in the methylene chain (e.g. in the 
aza-alkane series, Table 2) tended to reduce the activity compared to alkyl spacer. This 
is exemplified by the activity of compounds 1a and 2a (8 and 19.3 µM respectively) and 
their aza-analogues 5a and 5b (21.4 and 69.1 µM respectively). Another interesting 
result was that of the dicyclohexylguanidine 5c (IC50 = 2.4 µM) which was 9-fold more 
active than the guanidine analogue 5a (21.4 µM). This result might reflect better 
pharmacokinetic properties of the more lipophilic derivative 5c (i.e. to cross biological 
membranes).  
 
Tables 2 around here 
 
The dicyclohexylguanidine compound 17 (IC50 = 0.98 µM) displayed the best 
activity and selectivity (SI > 82) of all the 3-aza-1,6-hexanediamine derivatives (Table 
3). Again, it appeared that lipophilicity was an important factor for good activity. In this 
series, substitution of the secondary amino group with a phenethyl, 3(2-ethyl)indole or 
methyl group afforded molecules slightly more active than the parent compound 
(compare the activities of 10/5a, 11/5b and 16/5b).45 In addition, the amines protected 
with a carbobenzyloxy group (Cbz) were more active than their free amino counterparts 
(compare 8/9, 12/13 and 14/15. Regarding the effect of the substituent on the secondary 
nitrogen in the Cbz-protected series, the following results, in order of decreasing 
activity, were obtained: indole (13: 1 µM) > methyl (14: 3.1 µM) ~ phenethyl (8: 3.88 
µM) > CH2CH2OAc (18: 7.1 µM) > CH2CH2OH (20: 14 µM).  
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Table 3 around here 
 
Worth mentioning is the result obtained for the cyclic analogues 25 and 26 (Table 
4), which showed the same range of activity as the parent compound 14 (IC50 = 3.1 µM, 
Table 3) but a lower selectivity (SI = 27 and 18.6 respectively, compared to 41 for 14). 
This behaviour was also observed with the cyclic analogue 23 (71.2 µM) which 
displayed the same activity as the aliphatic parent 5b (69.1 µM).  
 
Table 4 around here 
 
Diphenyl derivatives (Table 5). In this series of bisguanidine and bis(2-
aminoimidazoline) diphenyl analogues (Entry 1-17), best activities were observed for 
the compounds bearing a guanidinium group (from 3- to 10-fold with respect to the 
imidazoline analogues). However, the 2-aminoimidazoline derivatives displayed, in 
general, better selectivity than the guanidine counterparts (compare the activity and 
selectivity of 31b/27b, 32b/28b, 34/29b and 32a/28a). In addition, replacement of the 
guanidine or 2-aminoimidazoline with a 2-aminoimidazole nucleus (compound 35, 
entry 18) produced a loss of activity of 20- and 63-fold compared to 28b and 32b 
respectively. Interestingly, the very lipophilic bis-phosphonium benzophenone 
derivative 37 showed a trypanocidal activity (IC50 = 0.414 µM) similar to that of the 
bisguanidinium diphenylketone 34 (0.206 mM) and a better selectivity (SI = 28.5 versus 
13.1).  
Notable is the effect of the N-substitution of the imidazoline and guanidine moieties 
(i.e. Boc, CH2CH(OEt)2). Boc protection afforded less active compounds compared to 
unprotected counterparts (compare 27a/27b, 29a/29b, 31a/31b, 32a/32b, 33a/ 33b and 
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40a/40b) with the exception of 28 and 30 in which the Boc substituents produced a 1.4 
and 12-fold increase in activity respectively (IC50 = 0.048 and 2.6 µM respectively) 
compared to the free imidazolinium cation (IC50 = 0.069 and 32.4 µM respectively). 
Moreover, the Boc substituents seemed to give somewhat less selective compounds (SI 
= 202 and 3072 for 28a and 28b respectively; SI = 7.9 and 29.5 for 32a and 32b). On 
the contrary, the 1,1-diethoxyethane substituent produced a great increase in selectivity, 
superior to 26- and 32-fold for 31c and 32c respectively, with only a slight loss in 
activity (2- and 10-fold respectively)  compared to the unsubstituted parent compounds 
31b and 32b.   
 
Table 5 around here 
 
Regarding the bridge linking both phenyl rings, the same behaviour was observed 
for the guanidinium and 2-aminoimidazolinium series, i.e. NH >> CH2 > CO > SO2 in 
order of decreasing activity (compare 27b-30b and 31b-33b, 34). When a piperazine 
moiety was used as bridge between both phenyl rings (Table 5, entry 21-25), the 2-
aminoimidazolinium compound 41b showed the best activity (0.118 µM) and also a 5 
times higher selectivity (SI = 881) with respect to the guanidinium analogue (SI = 172).  
 
 
Discussion 
Some of the compounds described in this manuscript were available in our in-house 
library. Since few of these molecules had been previously reported in the literature for 
their anti-trypanosomal activity (e.g. 1d,5 31b,8 33b10), we anticipated that our 
compounds would display trypanocidal action. Indeed, simple aliphatic diguanidines 
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were potent and selective trypanocides, with 3c (SI > 5294) being more selective than 
the control melarsoprol (SI = 3456). The potency of 3c is to be compared with that of 
synthalin (1,10-decanediguanidine)7 or 1,11-undecanediamidine, a trypanocidal drug 
which proved able to cure mice and rabbits infected with a strain of T.b. rhodesiense.6 
The 1,9-nonanediguanidine 3c could be considered as the bio-isostere of 1,11-
undecanediamidine with the supplementary amino groups of the guanidine moieties 
playing the role of the two supplementary methylene units, thus keeping approximately 
the same chain length in both molecules.  
In those series, the guanidine moiety afforded in general better trypanocidal drugs 
than the 2-aminoimidazoline one. Moreover, the presence of two cations was required 
for potent activity, which is in agreement with the results previously obtained by King 
et al.6 This assumption could probably be extended to the diphenyl series, according to 
the previous findings reported for aromatic diamidines and diguanidines,6,9,10 although 
this hypothesis was not tested here because mono-cationic aromatic compounds were 
not available in our library.   
For short methylene chains (n = 5, 6, 7), introduction of a secondary nitrogen atom 
into the alkyl spacer afforded less active molecules although further substitution of this 
nitrogen could increase slightly the activity (compounds 8-20). Conformational 
restriction of the aza-alkane molecules did not affect nor increase the trypanocidal 
action compared to their linear analogues (compounds 23, 25 and 26). The importance 
of lipophilicy of these molecules, facilitating drug uptake by the parasite by passive 
diffusion, was exemplified by the higher anti-trypanosomal activity of 5c with respect to 
5a. 
The most interesting results probably came from the diphenyl series with a NH 
bridge. The bis(2-aminoimidazoline) derivative 28b was extremely potent (IC50 = 69 
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nM) and also highly selective for the parasite (SI = 3072). The Boc-protected 
counterpart 28a had the same range of activity but a lower selectivity index (SI = 202). 
This result in particular might be relevant because of the higher lipophilicity of the Boc-
protected compound 28a. Late-stage cases of HAT involve CNS infection and hence, 
require drugs able to cross the blood-brain barrier. However, the Boc-protecting group 
is probably stable in the conditions of the in vitro assay but potentially could be 
metabolised in vivo to afford the unprotected derivative 28b. 
Changing the 2-aminoimidazolinium cations for guanidinium ones led to the most 
active compound of this screening: 32b (22 nM, SI = 29.5). The nature of the bridge 
linking both phenyl rings had a clear influence on the trypanocidal action of these 
compounds. Electron-donating groups such as NH, piperazine or CH2 afforded better 
trypanocides than electron-withdrawing groups such as C=O or SO2.  Such behaviour 
was consistent with the findings of Donkor et al. in the pentamidine congener series 
where electron-rich phenyl groups (e.g. phenoxy) afforded better trypanocides  than 
electron-poor phenyl rings (e.g. acetylated aniline or pyridine).15 
If we compare the different cationic species studied (i.e. guanidinium, 2-
aminoimidazolinium, phosphonium), the good activity and selectivity displayed by the 
bis-phosphonium derivative 37 (IC50 = 0.414 µM, SI = 28.5) is of particular interest. 
These results suggest that lipophilic bis-phosphonium diphenyl derivatives might be a 
good alternative (with potentially better pharmacokinetic properties) to the guanidine or 
2-aminoimidazoline derivatives. With respect to the guanidine cation, N-substitution 
with a diethoxyethane moiety afforded highly selective anti-trypanosomal agents (SI > 
754 and 767 for 31c and 32c respectively).  
Anti-trypanocidal efficacy of a drug depends on its effective uptake by the parasite. 
It is known that diamidines such as pentamidine, which have very slow rate of diffusion 
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across biological membranes, can be transported into the cell by a P2-amino-purine 
transporter that specifically recognises the main H2N-C(R1)=NR2 motif.
46,47 The 
guanidine molecules reported here also present this recognition motif. In the case of the 
diphenyl derivatives, most of the Boc-protected molecules (i.e. the most lipophilic) 
showed a weaker activity than the charged, unprotected, guanidinium analogues. This 
might account for a more efficient transport of the unprotected derivatives through the 
P2 transporter, although affinity assays for this transporter remain to be done.   
It is still too early to propose a mode of action of the compounds presented here and 
further studies are needed. However, a number of dicationic molecules belonging to the 
diamidine family (e.g. pentamidine) are known to bind to the minor-groove of DNA and 
their antiprotozoal activity is thought to be the result of that interaction (e.g. inhibition 
of DNA dependant enzymes or inhibition of transcription).48-50 In a recent article, 
Donkor et al. studied the trypanocidal activity of a series of conformationally restricted 
congeners of pentamidine.15 Although a direct correlation between the DNA binding 
affinity and the trypanocidal activity was not observed, the authors concluded that 
compounds with strong DNA affinity generally showed good trypanocidal activity in 
that series. In particular, N,N’-bis(4-amidinophenyl)piperazine (Figure 1) and N,N’-
bis(4-imidazolinophenyl)piperazine were the most potent trypanocides and also the 
strongest DNA binders in this series. According to the results of Donkor et al., we 
might expect good DNA binding affinity for compounds 40b and 41b, which are the 
guanidine and 2-aminoimidazoline analogues of these congeners respectively (vide 
infra). However, this hypothesis will need experimental confirmation. 
 Several compounds presented in this paper were first and foremost studied for 
different activities on the CNS (i.e. α1-adrenergic antagonism, I2-imidazoline binding 
site affinity or analgesic properties). The knowledge of these interactions (i.e. possible 
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side effects) is of importance because useful anti-trypanocidal agents are expected to 
penetrate the CNS to cure late-stage cases of HAT. The diphenyl compounds (Table 5, 
entries 5-8 and 12-15) present α1-adrenergic antagonist activity in various tissues.
26,51 In 
particular, the blood pressure and heart rate responses of two compounds (29b and 31b) 
had been tested on rats in vivo, suggesting a smaller magnitude of cardiovascular effects 
than the α1-adrenergic antagonist Doxazosin at the same dose.
52 On the other hand, the 
alkane derivatives (Table 1, 1a-d and 2a-d) showed a moderate to good affinity for the 
I2-imidazoline binding sites and α2-adrenoceptors in human brain membranes.
27 Finally, 
several aza-alkane derivatives (Tables 2 and 3: 4a-b, 5a-b, 6a-b, 7, 10, 11, 23) were 
tested for analgesic activity in mice.28 These data are relevant and should be taken into 
consideration when choosing possible lead compounds for in vivo assays. 
 
Conclusion 
We have reported here the screening for trypanocidal activity against T.b. 
rhodesiense of an in-house library of 62 compounds [i.e. alkane, diphenyl and aza-
alkane bisguanidine and bis(2-aminoimidazoline)] which were chosen for their 
structural similarity to the trypanocidal agents synthalin (1,10-decanediguanidine), and 
4,4’-diguanidinodiphenylmethane, and the polyamine N1-(3-amino-propyl)-propane-
1,3-diamine respectively. The original synthetic procedure for the preparation of 21 of 
these compounds was also reported.  
The results of the determination of in vitro anti-trypanosomal activity allowed 
drawing some conclusions about the SAR of these series of molecules. Most 
compounds displayed low micromolar anti-trypanosomal activity with five of them 
presenting a nanomolar inhibitory action on the parasite (1c, 1d, 28a, 28b and 32b). 
Few of these compounds, which showed an excellent in vitro activity as well as high 
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selectivity, e.g. 1c (IC50 = 49 nM; SI > 5294), 28b (IC50 = 69 nM; SI = 3072), 32b (IC50 
= 22 nM; SI = 29.5), 41b (IC50 = 118 nM; SI = 881) are promising lead compounds for 
anti-trypanosomal chemotherapy. The results of in vivo activity of these molecules will 
be reported in due course.  
Tropical diseases mainly affect third-world countries which usually lack research 
capacities and financial resources for investigation. The lack of available funds and 
research in this field put into light the importance of screening in-house libraries of 
molecules already available in order to save time and money in the discovery of new 
lead compounds for neglected diseases like HAT. 
 
Experimental Section 
 
Chemistry. All reaction solvents were purchased anhydrous and used as received. 
Other solvents used were reagent grade. Reactions were monitored by TLC using pre-
coated silica gel 60 F254 plates. Chromatography was performed either with silica gel 
60 PF254 (particle size 40-63 µm) or with a medium pressure chromatography system 
using KP-Sil™ 40S or 40M cartridges (particle size 32-63µm, 60Å). All reactions 
requiring anhydrous conditions or an inert atmosphere were performed under a positive 
pressure of N2. 
1H NMR and 13C NMR spectra were recorded at 200 and 50 MHz 
respectively, unless otherwise noted. Chemical shifts of the 1H NMR spectra were 
internally referenced to the residual proton resonance of the deuterated solvents: CDCl3 
(7.26 ppm), D2O (δ 4.6 ppm), CD3OD (3.49 ppm) and DMSO (δ 2.49 ppm). Chemical 
shifts of 13C NMR and 31P spectra were referenced with a capilar of DMSO-d6 (δ 39.5 
ppm) and H3PO4 (δ 0 ppm) respectively. IR spectra were recorded as KBr pellets or 
neat. Melting points were determined with a Reichert-Jung Thermovar apparatus and 
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are uncorrected. Mass spectra were recorded on a Hewlett Packard Series 1100 MSD 
spectrometer (ES, APCI) and on a VG Autospec spectrometer (FAB). Elemental 
analysis was performed on a Heraeus CHN-O Rapid analyser. Analytical results were 
within ± 0.4 % of the theoretical values unless otherwise noted. Analytical HPLC was 
run on a Beckman LC-168 HPLC with either a Waters Delta Pak 5µ-C18-100Å 
(3.9x150 mm) (column I) or a Varian Microsorb-MV-C18-100Å column (column II) 
using the following conditions: gradient time = 40 min and 15 min for columns I and II 
respectively, H2O/CH3CN (100:00:100) (TFA 0.1 %), flow rate = 1 mL/min, λ = 214 
and 254 nm. Preparative HPLC (compounds 5c and 17) was carried out using a Waters 
Deltaprep apparatus with a Waters prepak®-RCM Base column and detection at 214 
nm.   
 
Compounds 1a, 1b-1d, 2a, 2b, 2c, 2d, 3b, 3c, 3d, 4a- 6a,53 4b, 5b, 5d, 6b, 7, 8, 9, 11, 
12, 13, 21, 22, 23, 24, 27a-33a, 27b-33b and 34 were prepared as previously 
reported.26-28, 53  
 
N-{3-[(2-Guanidino-ethyl)-phenethyl-amino]-propyl}-guanidine (10).  A 
solution of 9 (0.5mmol) and S-methylisothiouronium sulfate (148 mg, 0.53 mmol) in 
dry MeOH (7 mL) was heated for 12 h at reflux. The solvent was removed by reduce 
pressure and the crude product dissolved in a mixture of H2O/EtOH was treated with a 
few drops of 5 % H2SO4. The solution was allowed to stand 3 days in the fridge and the 
supernatant was discarded. Acetone was added and the oily residue was triturated with a 
spatula until the product crystallised. The solid was dried in vacuo affording 10 as a 
highly hygroscopic colorless solid (104 mg, 46 %). 1H NMR (D2O) δ 7.3-7.0 (m, 5H); 
 21
3.6-2.8 (m, 12H); 1.87 (m, 2H); 13C NMR (D2O) δ 155.9 (br); 135.0; 128.1; 127.7; 
126.4; 53.0; 50.6; 49.9; 37.1; 35.4; 28.2; 22.7. LRMS (ES+) m/e: 307 [(M+H)]; 100 %].  
{3-[(2-Benzyloxycarbonylamino-ethyl)-methyl-amino]-propyl}-carbamic acid 
benzyl ester (14). NaBH3CN (100 mg, 1.49 mmol) was added to a solution of amine 5d 
(443 mg, 1.15 mmol) and 37 % aqueous formaldehyde (0.4 mL, 4.6 mmol). The 
reaction was stirred 4 h at room temperature and the solvents were removed by reduce 
pressure. The crude residue was partitioned between CHCl3 and water. The organic 
phase was collected and the aqueous phase was extracted 3 times with CHCl3 . Organic 
extracts were washed with brine, dried (Na2SO4) and concentrated by reduce pressure. 
Flash chromatography (40S cartridge) with CH2Cl2/MeOH (95:5) afforded the 
methylated amine 14 as a colorless solid (236 mg, 51 %); mp 60-62 oC; IR (KBr) ν 
3300, 2900, 2725, 1665, 1515, 1250, 1120, 960, 720, 685, 670 cm-1; 1H NMR (CDCl3) 
δ 7.4-7.2 (m, 10H); 5.6 (br, NH); 5.4 (br, NH); 5.07 (s, 2H); 5.05 (s, 2H); 3.3-3.1 (m, 
4H); 2.5-2.3 (m, 4H); 2.17 (s, 3H); 1.62 (quint, 2H, J = 6 Hz); 13C NMR (CDCl3) δ 
157.1; 137.3; 137.2; 129.0; 128.6; 128.5; 67.1; 67.0; 57.3; 55.9; 42.2; 40.1; 38.9; 27.4; 
LRMS (ES+) m/e: 400 [(M+H), 100 %]; Anal. (C22H29N3O4) C, H, N. 
N
1
-(2-Amino-ethyl)-N
1
-methyl-propane-1,3-diamine (15). Catalytic 
hydrogenation of a suspension of 14 (230 mg, 0.57mmol), 10 % Pd-C (23 mg) and 1M 
HCl (1 mL) in MeOH (30 mL) under a 36 Psi hydrogen pressure for 24 h at room 
temperature afforded the HCl salt of 15 as a colorless oil (118 mg, quantitative). 1H 
NMR (D2O) δ 3.0-2.8 (m, 4H); 2.58 (t, 2H, J = 6.8 Hz); 2.46 (t, 2H, J = 7.6 Hz); 2.16 
(s, 3H); 1.74 (quint, 2H, J = 7.6 Hz); 13C NMR (D2O) δ 54.8 (t); 54.5 (t); 41.0 (q); 38.5 
(t); 37.0 (t); 24.5 (t); LRMS (APCI+) m/e 132 [(M+H), 100 %]. Anal. (C6H20N3Cl3 / 0.3 
H2O) calcd: C, 29.47; H, 8.49; N, 17.19; found: C, 29.35; H, 8.40; N, 17.00.  
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N,N'-di[2-(4,5-dihydro-1H-imidazol-2-ylamino)-ethyl]-N'-methyl-propane-
1,3-diamine (16). A solution of 15 (110 mg, 0.84 mmol), 2-methylmercapto-4,5-
dihydro-1H-imidazole iodide (410 mg, 1.76 mmol) in EtOH (10 mL) was heated 24 h at 
reflux (CAUTION: the noxious gas CH3SH is evolved during the reaction and it should 
be trapped with a concentrated aqueous NaOH solution). The solvent was removed by 
reduce pressure and the crude compound was purified by formation of its picrate salt: a 
hot solution of picric acid (400 mg in 5 mL H2O) was added to the hot reaction mixture 
and the flask was allowed to stand in the fridge for one week. The crystals were 
collected by filtration and rinsed successively with water, hexane and Et2O. Picrate of 
16: yellow solid (302 mg, 53 %); mp  81-83 oC; 1H NMR (400MHz, DMSO-d6) δ 9.94 
(br s, 1H); 9.25 (br s, 1H); 8.54 (s, 4H); 8.18 (t, 1H, J = 5.7 Hz); 8.13 (t, 1H, J = 4.8 
Hz); 7.65 (br, 1H); 3.80 (s, 3H); 3.58 (s, 4H); 3.55 (s, 4H); 3.1 (m, 4H); 2.8-2.7 (m, 4H); 
1.8 (br, 2H); 13C NMR (50 MHz, DMSO-d6) δ 170.5; 160.9 (s); 159.4 (s); 141.5 (s); 
125.3 (d); 124.8 (s); 53.6 (br, t); 53.0 (t); 45.2 (t); 42.6 (t) ; 40.2 (q); 37.2 (t); LRMS 
(FAB+) m/e 268 [(M+H)]. Anal. (C24H31N13O14) C, H, N. 
3-Azahexane-1,7-(N,N’-dicyclohexyl)diguanidine (5c). A solution of 3-(2-
aminoethylamino)propylamine (1 mL, 8.5 mmol) and DCC (3.7 g, 17.9 mmol) in dry 
CH3CN (25 mL) was stirred 4 days at room temperature under argon atmosphere. The 
solvent was removed by reduce pressure and the crude oil was dissolved in Et2O. A 
current of HClg was bubbled into the solution for 2 min. The white precipitate was 
collected, rinsed with Et2O and dried in vacuo affording a mixture of the di- and tri-
substituted compounds 5c and 17 which were separated by preparative HPLC using the 
following eluent system: H2O/CH3CN (100:00:100) (TFA 0.1 %). Trifluoroacetate of 
5c: white solid; mp 88-93 oC; 1H NMR (400 MHz, CDCl3) δ 3.45 (t, 2H, J = 6.3 Hz); 
3.6-3.25 (m, 10H); 3.18 (t, 2H, J = 7 Hz); 2.95 (br t, 2H); 1.82 (q, 2H, J = 7.8 Hz); 1.69 
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(br s, 8H); 1.60 (br d, 8H); 1.46 (br d, 4H); 1.16 (t, 16H, J = 10 Hz); 1.0 (br m, 5H); 13C 
NMR (100 MHz, CDCl3) δ 163.7 (TFA); 154.0 (s); 154.0 (s); 117.6 (TFA); 52.6 (d); 
52.5 (d); 47.3 (t); 46.5 (t); 39.3 (t); 38.9 (t); 33.4 (t); 33.4 (t); 26.5 (t); 25.8 (t); 25.7 (t); 
LRMS (ES+) m/e 265,9 [(M+2H), 100 %]; 644.6 [(M+TFA)]; 758.6 [(M+2TFA)]; 
HPLC (column II): Rt = 9.37 min (100 %).  
3-Azahexane-1,3,7-(N,N’-dicyclohexyl)triguanidine (17). Trifluoroacetate of 
17: white flocculent solid. 1H NMR (500 MHz, CD3OD) δ 3.73-3.60 (m, 8H); 3.56-3.44 
(m, 6H); 2.14-1.8 (m, 30H); 1.7-1.3 (m, 32H); 13C NMR (125 MHz, CD3OD) δ 160.1 
(s); 154.2 (s); 56.0 (d); 52.6 (d); 52.6 (d); 49.8 (t); 47.7 (t); 39.9 (t); 39.7 (t); 34.5 (t); 
33.9 (t); 33.9 (t); 28.2 (t); 26.2 (t); 26.2 (t); 26.1 (t) ; 26.1 (t); 26.0 (t) ; LRMS (ES+) m/e 
369 [(M+2H), 100 %]; 246.5 [(M+3H)]; HPLC (column I): Rt = 30.55 min (99.58 %). 
{3-[(2-Benzyloxycarbonylamino-ethyl)-(2-chloro-ethyl)-amino]-propyl}-
carbamic acid benzyl ester (19). Chloroacetaldehyde (50 % in water, 1.5 mL, 11.6 
mmol) was added to a solution of 5d (1.11 g, 2.9 mmol) in CH3CN (20 mL). After a 
few minutes, AcOH (0.5 mL, 8.5 mmol)) was added, followed 5 min later by 
NaBH(OAc)3 (1.24g, 5.8 mmol). The reaction mixture was stirred for 4 h at room 
temperature adjusting the pH to 5-6 with AcOH during the course of the reaction. The 
reaction was quenched by careful addition of 5 % NaHCO3 and diluted with CH2Cl2. 
The organic phase was separated and the aqueous phase was extracted 3 times with 
CH2Cl2. Combined organic extracts were washed with brine, dried (Na2SO4) and 
concentrated by reduce pressure.  Chromatography (40M cartridge) with petroleum 
ether/acetone (80:20) yielded the acetyl side-product 18 (16 %) and the expected chloro-
derivative 19 as an oil that solidified as a yellowish pasty residue (450 mg, 35 %); IR 
(KBr): ν: 1680; 1415; 1240; 755; 713; 675 cm-1; 1H NMR (CDCl3) δ 7.29 (br s, 10H); 
5.67 (br, NH); 5.60 (br, NH); 5.09 (s, 2H); 5.08 (s, 2H); 3.43 (t, 2H, J = 6.1 Hz); 3.3-3.1 
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(m, 4H); 2.68 (t, 2H, J = 6.3 Hz); 2.6-2.4 (m, 4H); 1.56 (quint, 2H, J = 6.4 Hz); 13C 
NMR (CDCl3) δ 157.0 (2C); 137.1; 128.8; 128.3; 66.8; 56.0; 54.0; 52.4; 42.5; 39.7; 
39.3; 27.5; LRMS (ES+) m/e 448.5 [(M+HCl), 100 %]; 412 [(M+H)]; Anal. 
(C23H30N3O4Cl / H2O) calcd: C, 59.29; H, 6.92; N, 9.02; found: C, 59.27; H, 7.26; N, 
9.02. 
Acetic acid 2-[(2-benzyloxycarbonylamino-ethyl)-(3-
benzyloxycarbonylamino-propyl)-amino]-ethyl ester (18). (223 mg, 16 %); 1H NMR 
(CDCl3) δ 7.28 (br s, 10H); 5.68 (br, NH); 5.52 (br, NH); 5.04 (s, 2H); 5.02 (s, 2H); 
4.03 (t, 2H, J = 5.6 Hz); 3.25-3.05 (m, 4H); 2.60 (t, 2H, J = 5.6 Hz); 2.55-2.35 (m, 4H); 
1.90 (s, 3H); 1.55 (quint, 2H); 13C NMR (CDCl3) δ 171.5; 157.0; 156.9; 137.1; 128.9; 
128.5; 128.4; 66.95; 66.87; 62.4; 54.0; 52.7; 43.5; 39.9; 39.2; 27.3; 21.2; LRMS (ES+) 
m/e 472 [(M+H), 100%]. Anal. (C25H33N3O6) C, H, N. 
{3-[(2-Benzyloxycarbonylamino-ethyl)-(2-hydroxy-ethyl)-amino]-propyl}-
carbamic acid benzyl ester (20). A solution of bromoethanol (0.03 mL, 0.42 mmol) in 
CH3CN (1 mL) was added to a solution of 5d (208 mg, 0.54 mmol) in CH3CN (4 mL). 
The reaction mixture was refluxed 12 h and the solvent was removed by reduce 
pressure. The crude product was purified by chromatography with EtOAc/MeOH 
(80:20) and the resulting compound dissolved in a little CH2Cl2 was filtered on a path of 
Celite affording the pure product 20 (124 mg, 69 %). 1H NMR (300 MHz, CDCl3) δ 
7.22 (br s, 10H); 5.63 (br, 1H); 5.46 (br, 1H); 4.97 (s, 4H); 3.44 (t, 2H, J = 5 Hz); 3.1 
(m, 5H); 2.5-2.3 (m, 6H); 1.49 (m, 2H); 13C NMR (75 MHz, CDCl3) δ 156.76; 156.57; 
136.5; 128.3; 127.9; 66.4; 59.1; 55.8; 53.7; 51.3; 38.9; 38.6; 27.0; IR (neat) ν 3500-
3300 (br); 2905; 1680; 1515; 1235; 715; 675 cm-1; LRMS (ES+) m/z 430 [(M+H)], 542 
[(M+Na), 100%]; Anal. (C23H31N3O5 / 1 H2O) calcd: C, 61.73; H, 7.43; N, 9.39; found: 
C, 61.83; H, 6.98; N, 8.82. 
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3-(3-Benzyloxycarbonylamino-propyl)-imidazolidine-1-carboxylic acid 
benzyl ester (25). To a solution of amine 5d (1.06 g, 2.7 mmol) and formaldehyde (37 
% in H2O, 1.5 mL, 13.5 mmol) in CH3CN was added NaBH3CN (226 mg, 3.6 mmol). 
After 10 min, few drops of AcOH were added to the cloudy solution to adjust the pH to 
6-7. The reaction was stirred 17 h at room temperature and the solvent was removed by 
reduce pressure. The crude residue was treated with water and 1M NaOH was added to 
adjust the pH to 10-11. The aqueous phase was extracted 3 times with CH2Cl2 and the 
organic extracts were dried (Na2SO4) and concentrated by reduce pressure. The crude 
oil was chromatographed (40M cartridge) with CH2Cl2/MeOH (98:2). The six-
membered heterocycle 26 was eluted first followed by 25. Compound 25: 1H NMR 
(300MHz, CDCl3) δ 7.25 (m, 10H); 5.3 (br, 1H, NH); 5.04 (s, 2H); 4.99 (s, 2H); 3.94 (s, 
1H); 3.89 (s, 1H); 3.37 (td, 2H, J = 8.9 and 9.3 Hz); 3.17 (td, 2H, J  = 9.0 and 9.6 Hz); 
2.70 (m, 2H); 2.43 (br t, 2H, J = 9 Hz); 1.58 (quint, 2H, J = 9.7 Hz); 13C NMR 
(300MHz, CDCl3) δ 157.0; 154.4; 137.2; 129.0; 128.6; 68.8; 68.5; 67.4; 67.1; 53.4; 
52.6; 52.2; 44.9; 44.7; 43.6; 40.2; 28.8; LRMS (ES+) m/z 398 [(M+H), 100 %]. 
3-(2-Benzyloxycarbonylamino-ethyl)-tetrahydro-pyrimidine-1-carboxylic 
acid benzyl ester (26). 
1H NMR (300 MHz, CDCl3) δ 7.3 (br s, 10H, aro); 5.5 (br, 1H, 
NH); 5.1 [s, 2H, PhCH2OC(O)NH]; 5.06 [s, 2H, PhCH2OC(O)N]; 4.12 (s, 2H, NCH2N); 
3.48 (br t, 2H, J = 8.2 Hz, CbzNCH2); 3.22 (br m, 2H, CH2NHCbz); 2.67 (br t, 2H, 
NCH2CH2); 2.49 (m, 2H, NCH2CH2NHCbz); 1.53 (m, 2H, CH2CH2CH2); 
13C NMR (75 
MHz, CDCl3) δ 156.7 [s, C(=O)NH]; 155.28 [s, C(=O)N]; 136.94 (s, aro); 136.86 (s, 
aro); 128.7 (d, aro); 128.3 (d, aro); 128.1 (d, aro); 67.4 [t, PhCH2OC(O)NH]; 66.7 [t, 
PhCH2OC(O)N]; 65.1 (t, NCH2N); 51.9 (t, NCH2CH2); 44.1 (t, CbzNCH2); 38.3 (t, 
CH2NHCbz); 22.5 (t, CH2CH2CH2); LRMS (ES
+) m/z 398 [(M+H), 100 %]. 
4,4'-Bis[N
3
-(2,2-diethoxyethyl)guanidino]diphenylmethane (31c). A 1M ether 
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solution of 2,2-diethoxy-ethyl-carbodiimide (11.1 mL, 11.1 mmol) was added to a 
solution of  4,4’-diaminodiphenylmethane (1.05 g, 5.3 mmol) in dry EtOH under N2. 
Methanesulfonic acid (0.69 mL, 10.6 mmol) was added drop wise to the clear reaction 
mixture and a white precipitate formed immediately. The reaction was refluxed 44 h and 
then poured into 0.5 M aqueous NaOH solution. The aqueous phase was extracted 
(3×CH2Cl2). Organic extracts were dried (Na2SO4) and concentrated by reduce pressure. 
The guanidine 31c was crystallised with CH2Cl2 and washed with Et2O. Some more 
compound was obtained by precipitation of the mother liquor with Et2O. Colorless solid 
(926 mg, 34 %); mp 188-190 oC; 1H NMR (CDCl3/CD3OD) δ 7.0 (d, 4H, J = 7.5 Hz); 
6.73 (d, 4H, J = 7.5 Hz); 4.44 (t, 2H, J = 4.8 Hz); 3.75 (s, 2H); 3.8-3.4 (m, 8H); 3.19 (d, 
4H, J = 4.8 Hz); 1.12 (t, 12 H, J = 7 Hz); 13C (CDCl3/CD3OD) 
δ 154.5; 146.6; 136.1; 130.2; 124.2; 102.6; 63.8; 45.1; 41.2; 15.6; LRMS (EI) m/z 514 
[(M+.), 70 %], 485 [(M-29), 100 %]; Anal. (C27H42N6O4) C, H, N.  
4,4'-Bis[N
3
-(2,2-diethoxyethyl)guanidino]diphenylamine (32c). Same 
procedure as 31c starting from 4,4’-diaminodiphenylamine (421 mg, 2.1 mmol), 2,2-
diethoxy-ethyl-carbodiimide (4.6 mL, 4.6 mmol) and methanesulfonic acid (0.27 mL, 
4.2 mmol). The crude product dissolved in EtOH was treated with Et2O. The solid 
precipitate was filtered off and the mother liquor was concentrated by reduce pressure. 
The residue was dissolved in MeOH and 32c was isolated by Et2O mediated 
precipitation (707 mg, 65 %); Methanesulfonate salt of 32c: purple solid; IR (KBr) ν 
1625; 1600; 1480; 1175; 1160; 1025; 1015; 750; 737 cm-1; 1H NMR (D2O) δ 7.11 (s, 
8H); 4.65 (m, 2H); 3.8-3.4 (m, 8H); 3.33 (m, 4H); 1.11 (t, 12H, J = 7.1 Hz); 13C NMR 
(D2O) δ 156.7; 143.1; 127.8; 126.9; 118.9; 101.3; 65.0; 44.9; 15.2; LRMS (ES+) m/e 
516 [(M+H), 100 %]. Anal. (C28H49N7O10S2 / 2 H2O) calcd: C, 45.21; H, 7.18; N, 13.18; 
S, 8.62; found: C, 44.80; H, 7.02; N, 12.70; S, 9.08. 
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4,4’-Bis(2-imidazolylamino)diphenylamine (35). In a flask cooled to 0 oC, was 
dissolved the guanidine 32c (350mg, 0.68 mmol) in 6 M HCl (5 mL). After stirring 3 h 
at room temperature, 10 % NaOH was added until a precipitate formed (pH > 11). The 
reaction mixture was stirred 75 min and was poured into a 1M NaOH solution. The 
aqueous phase was extracted with CH2Cl2. The crude product was collected by filtration 
of the aqueous phase. The crude solid was dissolved in boiling water (10 mL) and the 
flask was allowed to stand overnight at room temperature. The product was collected by 
filtration, washed several times with H2O and dried in vacuo at 50 
oC affording the free 
base of 35 as a purple solid (82 mg). The hydrochloride salt was prepared in the 
following manner: to 35 dissolved in H2O was added 3 N HCl until pH 2 was reached. 
The compound was lyophilised, dissolved in MeOH and purified by Et2O mediated 
precipitation. Purple solid (51 mg, 19 %); mp > 200 oC (dec.); IR (KBr) ν 1650; 1590; 
1500; 1310; 815; 670 cm-1; 1H NMR (D2O) δ 7.15 (br s, 8H); 6.76 (br s, 4H); 13C NMR 
(D2O) δ 145.9 (s); 142.5 (s); 130.2 (s); 125.4 (d); 119.8 (d); 114.0 (d); LRMS (ES+) m/e 
332 [(M+H), 100 %]; 166.6 [(M+2H)]; Anal. (C18H20Cl3N7) calcd: C, 49.05; H, 4.57; N, 
22.25; found: C, 49.71; H, 4.45; N, 21.66. 
Bis-(4-bromomethyl-phenyl)-methanone (36). A solution of 4,4’-
dimethylbenzophenone (1 g, 4.8 mmol), NBS (1.71 g, 9.6 mmol) and four drops of t-
BuOOH in CCl4 (15 mL) was heated at reflux for 18 h under argon atmosphere. The 
insoluble succinimide was filterered off and the solvent was removed by reduce 
pressure. The pure product was obtained by crystallisation from CH2Cl2 as colorless 
needles (387 mg, 22 %); mp 135-137 oC; IR (KBr) ν 1630, 1585, 1390, 1255, 1155, 
905, 665  cm-1; 1H NMR (CDCl3) δ 7.78 (d, 4H, J = 8.4 Hz); 7.51 (d, 4H, J = 8.4 Hz); 
4.57 (s, 4H); 13C NMR (CDCl3) δ 195.8; 142.9, 137.8, 131.1, 129.6, 32.9; Anal. 
(C15H12Br2O / 0.5 H2O) calcd: C, 47.78; H, 3.47; found: C, 47.87; H, 3.08. 
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Tri-n-pentylphosphine. To a suspension of magnesium (1.96 g) in dry THF (50 
mL) under argon, was added a solution of 1-bromopentane (10 mL, 80.7 mmol) in THF 
(20 mL). The resulting reaction mixture was heated at reflux for 20min. Then, the 
reaction was cooled to -78 oC and a solution of phosphorous trichloride (1.74 mL, 20 
mmol) in THF (10 mL) was added drop wise. The reaction was stirred 30 min at – 78 ºC 
and the cold bath was removed. The reaction was allowed to warm up to room 
temperature and was then heated at reflux for 30 min. The reaction was quenched with 
saturated NH4Br solution (20 mL). The precipitate was filtered off under argon 
atmosphere and the crude product was distilled under vacuum, affording the tri-n-
pentylphosphine as a colorless oil (1.305 g, 27 %). The product was conserved under 
argon in the fridge. Bp (3 mm Hg) 115-125 oC; 1H NMR (CDCl3) δ 1.61 (m, 6H); 1.36 
(m, 18H); 0.88 (m, 9H); 13C NMR (D2O) δ 33.9 (d, J31P-13C = 13.7 Hz), 29.1, 27.8, 
22.8, 22.0, 14.5; 31P NMR (CDCl3) δ 50.23. 
4,4’-Bis(tri-n-pentylphosphonium)benzophenone bromide (37). A solution of 
36 (344 mg, 0.93 mmol) and tri-n-pentylphosphine (1.02 g, 4.2 mmol) in dry toluene 
(10 mL) was heated at reflux for 24 h. The precipitate that had formed while cooling the 
reaction mixture was triturated with a spatula until a solid formed. The solid was 
collected by filtration, rinsed with dry toluene and dried in vacuo at 70 ºC. Colorless 
hygroscopic solid (748 mg, 94 %); Spectroscopic data are in agreement with the 
literature.37 LRMS (FAB+) m/e 695.5 [(M+); 100%]; Anal. (C45H78OP2Br2) C, H. 
1,4-Bis-(4-nitro-phenyl)-piperazine (38).
54 A solution of 1-(4-nitro-phenyl)-
piperazine (2.58 g, 12.5 mmol) and 1-fluoro-4-nitrobenzene (599 mg, 4.16 mmol) in 
DMSO (15 mL) was heated 60 h at 100 oC. The cool reaction was poured into water (50 
mL). The precipitate was collected by filtration and rinsed with a small quantity of 
water. The product was first crystallised with PhMe/EtOH and rinsed with cold toluene 
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and cold EtOH respectively. The pure compound was obtained as a red solid by 
crystallisation with CH3CN (1g, 73 %). Mp 265-266 
oC [Lit.54 261 ºC, PhNO2]; 
1H 
NMR (DMSO-d6) δ 8.1 (d, 4H, J = 9 Hz); 7.0 (d, 4H, J = 9 Hz); 3.71 (s, 8H); 13C NMR 
(DMSO-d6) δ 153.9; 136.8; 125.6; 111.9; 45.1. Anal. (C16H16N4O4 / 0.8 H2O) calcd: C, 
56.10; H, 5.18; N, 16.36; found: C, 56.12; H, 5.35; N, 16.24. 
1,4-Bis-(4-amino-phenyl)-piperazine (39).
42
 The nitro compound 38 ((705 mg, 
2.1 mmol) was dissolved in HCl saturated methanolic solution (70 mL). The solution 
was hydrogenated (40 Psi H2) in the presence of 10 % Pd-C (165 mg) for 14 h at room 
temperature. The catalyst was filtered off and the solvent was removed by reduce 
pressure affording the crude hydrochloride of 39. Recrystallisation with EtOH afforded 
the pure HCl salt of 39 (300 mg, 41%); mp > 350 oC; 1H NMR (D2O) δ 7.24 (s, 8H); 
3.49 (s, 8H); LRMS (ES+) m/z 269 [(M+H), 100 %], 135 [(M+2H)]. Anal. (C16H24Cl4N4 
/ 1.7 H2O) calcd: C, 43.40; H, 6.24; N, 12.65; found: C, 43.08; 5.49; N, 12.83. 
1,4-Bis-[4-(N
2
,N
3
-di(tert-butyloxycarbonyl)guanidino)-phenyl]-piperazine 
(40a). To a solution of 39 (54 mg, 0.2 mmol), N,N’-di(tert-butoxycarbonyl)thiourea 
(122 mg, 0.44 mmol), and Et3N (0.14 mL, 1 mmol) in DMF (2 mL) at 0 
oC under N2 
was added HgCl2 (119 mg, 0.44 mmol) at once. A precipitate formed immediately. The 
resulting dark reaction mixture was stirred 30 min at 0 oC and 2.5 days at room 
temperature. The reaction was diluted with CH2Cl2 and filtered through a path of Celite. 
The filter cake was rinsed with CH2Cl2. the organic phase was washed with brine, dried 
(MgSO4) and concentrated. Non-mobile impurities were removed by a short flash 
chromatography on silica with Hexane/EtOAc (75:25). The pure product was obtained 
by crystallisation from hexane. Yellowish solid (110 mg, 73 %); mp > 300 oC dec.; 1H 
NMR (CDCl3) δ 11.64 (br, 2H); 10.17 (br, 2H); 7.47 (d, 4H, J = 8.9 Hz); 6.92 (d, 4H, J 
= 8.9 Hz); 3.27 (s, 8H); 1.5 (br s, 36H); 13C NMR (CDCl3) δ 164.2; 154.1; 153.9; 149.2; 
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130.0; 124.1; 117.4; 84.0; 79.9; 50.3; 28.7; LRMS (ES+) m/z 753 [(M+H)]; Anal. 
(C38H56N8O8 / 0.7 C6H14) calcd: C, 62.37; H, 8.16; N, 13.79; found: C, 62.23; H, 8.80; 
N, 14.11. 
1,4-Bis-(4-guanidino-phenyl)-piperazine (40b). TFA (2 mL) was added to a 
stirred solution of 40a (37 mg, 0.049 mmol) in CH2Cl2 (3 mL). After 2 days, the 
volatiles were removed by reduce pressure and the product was precipitated by addition 
of Et2O. The compound was dried in vacuo affording 40b as a greenish hygroscopic 
solid (25 mg, 88 %). Trifluoroacetic salt of 40b. 1H NMR (D2O) δ 7.19 (m, 8H); 3.36 
(s, 8H); 13C NMR (D2O) δ 156.2; 148.4; 128.2; 127.1; 118.7; 49.4; LRMS (ES+) m/z 
353 [(M+H)], 177 [(M+2H), 100%]. Anal. (C24H27F9N8O6) calcd: C, 41.51; H, 3.92; N, 
16.13; found: C, 41.52; H, 4.33; N, 17.04. 
Di(tert-butyl) 2-(4-[4-(4-[1,3-di(tert-butyloxycarbonyl)tetrahydro-1H-2-
imidazolyliden]aminophenyl)piperazino]phenylimino)-1,3-
imidazolidinedicarboxylate (41a). Same procedure as 40a starting from the HCl salt of 
39 (111 mg, 0.27 mmol), Et3N (0.37 mL, 2.7 mmol), HgCl2 (160 mg, 0.59 mmol) and 
using N,N’-di(tert-butoxycarbonyl)imidazoline-2-thione (178 mg, 0.59 mmol) as 
reagent for the introduction of the imidazoline nucleus. Flash chromatography with 
Hexane/EtOAc (50:50) afforded the product as a colorless solid (143 mg, 66 %). 1H 
NMR (CDCl3) δ 6.9 (m, 8H); 3.79 (s, 8H); 3.20 (s, 8H); 1.31 (s, 36H); 13C NMR 
(50MHz, CDCl3) δ 150.3 (s); 147.2 (s); 141.5 (s); 138.5 (s); 122.1 (d); 117.3 (d); 82.4 
(s); 50.4 (t); 42.9 (t); 27.7 (q); Anal. (C42H60N8O8) C, H, N. 
1,4-bis[4-(4,5-dihydro-1H-2-imidazolylamino)phenyl]piperazine (41b). TFA 
(2 mL) was added to a stirred solution of 41a (65 mg, 0.08 mmol) in CH2Cl2 (3 mL). 
After 12 h, the volatiles were removed by reduce pressure and the product dissolved in 
water was extracted with CH2Cl2 to remove organic soluble impurities. The water was 
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evaporated and the product was dried in vacuo to afford 41b as a greenish hygroscopic 
solid. 1H NMR (D2Ο) δ 7.3-7.0 (br m, 8H); 3.63 (s, 8H); 3.59 (s, 8H); 13C NMR 
(CD3OD, 75 MHz) δ 161.1; 152.5; 128.7; 127.4; 118.6; 50.6; 44.5; LRMS (ES+) m/z 
405 [(M+H)]; 203.2 [(M+2H), 100 %]; Anal. (C26H30F6N8O4) C, H, N. 
 
Biological tests 
In Vitro antitrypanosomal activity against Trypanosoma brucei rhodesiense. 
Minimum Essential Medium (50 µl) supplemented with 25 mM HEPES, 1g/l additional 
glucose, 1% MEM non-essential amino acids (100x), 0.2 mM 2-mercaptoethanol, 2mM 
Na-pyruvate, 0.1mM hypoxanthine and 15% heat inactivated horse serum was added to 
each well of a 96-well microtiter plate. 3-fold serial drug dilutions were prepared in 
duplicate in the columns covering a range from 90 µg/ml to 0.123 µg/ml. Then 104 
bloodstream forms of T. b. rhodesiense STIB 900 in 50 µl was added to each well and 
the plate incubated at 37 °C under a 5 % CO2 atmosphere for 72 h. Alamar Blue (10 µl)
 
was then added to each well and incubation continued for a further 2-4 h. Then the 
plates were read with a Spectramax Gemini XS microplate fluorometer (Molecular 
Devices Cooperation, Sunnyvale, CA, USA) using an excitation wave length of 536 nm 
and an emission wave length of 588 nm. Data are analysed using the microplate reader 
software Softmax Pro (Molecular Devices Cooperation, Sunnyvale, CA, USA). 
 
In vitro cytotoxicity with L-6 cells. Assays were performed in 96-well microtiter 
plates, each well containing 100 µl of RPMI 1640 medium supplemented with 1% L-
glutamine (200mM) and 10% fetal bovine serum, and 4 x 10 4 L-6 cells (rat skeletal 
myoblasts) with or without a serial drug dilution columns covering a range from 90 
µg/ml to 0.123 µg/ml. Each compound was tested in duplicate. After 72hours of 
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incubation the plates were inspected under an inverted microscope to assure growth of 
the controls and sterile conditions. 10µl of Alamar Blue was then added to each well 
and the plates incubated for another 2 hours. Then the plates were read with a 
Spectramax Gemini XS microplate fluorometer (Molecular Devices Cooperation, 
Sunnyvale, CA, USA) using an excitation wave length of 536 nm and an emission wave 
length of 588 nm. Data were analysed using the microplate reader software Softmax Pro 
(Molecular Devices Cooperation, Sunnyvale, CA, USA). 
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Table 1. Structure, in vitro trypanocidal activity and cytotoxicity of guanidine and 2-
aminoimidazoline alkane derivatives 1a-3d. 
 
R1 (CH2)n R2
 
 
 
Compound 
 
n 
 
 
 
   R1 
 
R2 T. brucei rhodesiense 
IC50 (µM)a 
 
Cytotoxicity  
L6-cells 
IC50 (µM) 
Selectivityb 
 
 
1a 6 8.05 >302 > 37 
1b 8 0.251 >276 > 1100 
1c 9 0.049 >265 > 5294 
1d 12 
 
 
H
N
NH
NH2 
0.047 0.63 13 
2a 6 19.3 - - 
2b 8 0.453 4.2 9.4 
2c 9 0.225 16 71 
2d 12 
 
HN
N
H
N
 
 
0.107 2.35 22 
3b 8 H 49.1 - - 
3c 9 H 19.9 - - 
3d 12 H 
 
H
N
NH
NH2 
11.0 19.6 1.8 
a Controls: melarsoprol IC50 = 5.5 nM (SI= 3456); diminazene diaceturate IC50= 8.9 nM; CGP 
40215 IC50 = 4.5 nM [ref 43]. 
b Selectivity index (SI) expressed as the ratio [IC50 L6-cells / IC50 
T.b. rhodesiense] 
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Table 2. Structure, in vitro trypanocidal activity and cytotoxicity of guanidine and 2-
aminoimidazoline aza-alkane derivatives 4a-7. 
 
R = Gua: R = Imi:
H
N
NH
NH2
HN
N
H
N R = Gua-C6H11:
N
N
HNH
R X R
 
 
 
Compd 
 
R X 
 
T. brucei rhodesiense 
IC50 (µM)a 
Cytotoxicity  
L6-cells 
IC50 (µM) 
4a Gua 16.1 - 
4b Imi 
H
N
 
84.4 - 
5a Gua 21.4 - 
5b Imi 69.1 - 
5c Gua-C6H11 
N
H  
 2.4 - 
6a Gua 21.2 - 
6b Imi NH  29.7 - 
7 Imi N
H
 
113.1 - 
a Controls: melarsoprol IC50 = 5.5 nM (SI= 3456); diminazene diaceturate IC50= 8.9 nM; CGP 
40215 IC50 = 4.5 nM [ref 43]. 
b Selectivity index (SI) expressed as the ratio [IC50 L6-cells / IC50 
T.b. rhodesiense] 
 
 42
Table 3. Structure, in vitro trypanocidal activity and cytotoxicity of 3-aza-1,6-
hexanediamine derivatives 8-20. 
 
R
H
N N N
H
R
R' N
N
H
NH
NH2R:  Gua = Imi = O
O
Cbz =
 
 
 
Compd 
 
R 
 
 
 
R’ T. brucei rhodesiense 
IC50 (µM)a 
 
Cytotoxicity  
L6-cells 
IC50 (µM) 
Selectivityb 
 
 
8 Cbz 3.88 24.7 6.4 
9 H 17.4 214 12 
10 Gua 4.5 >199 > 43 
11 Imi 
 
 
 
27.6 - - 
 
12 
 
H 13.8 
 
- - 
13 Cbz 
 
N
H
 
1.0 7.8 7.8 
14 Cbz 3.1 130 41 
15 H 61.8 - - 
16 Imi 
 
CH3 
46.6 - - 
17 Gua-C6H11 Gua-C6H11 0.98 >83 > 82 
18 Cbz OAc
 
7.1 >191 > 26 
20 
Cbz 
OH
 
14.0 116 8.3 
a Controls: melarsoprol IC50 = 5.5 nM (SI= 3456); diminazene diaceturate IC50= 8.9 nM; CGP 
40215 IC50 = 4.5 nM [ref 43]. 
b Selectivity index (SI) expressed as the ratio [IC50 L6-cells / IC50 
T.b. rhodesiense] 
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Table 4. Structure, in vitro trypanocidal activity and cytotoxicity of 3-aza-1,6-hexanediamine cyclic derivatives 21-26. 
 
N
N
H
O
OR:  Boc = Imi = O
O
Cbz =
 
 
 
Compd 
 
Structure 
 
R T. brucei rhodesiense 
IC50 (µM)a 
Cytotoxicity L6-
cells 
IC50 (µM) 
Selectivityb 
 
21 H 57.9 - - 
22 Boc 30.3 - - 
23 Imi 71.2 - - 
 
24 
 
 
NN RNR
 
N
H
S
NHBoc
 
 
12.6 - - 
25 N NR
RHN
 
Cbz 3.9 
 
106 
 
27 
 
26 
N NR R 
Cbz 4.78 
 
89 
 
18.6 
 
a Controls: melarsoprol IC50 = 5.5 nM (SI= 3456); diminazene diaceturate IC50= 8.9 nM; CGP 40215 IC50 = 4.5 nM [ref 43]. 
b Selectivity index (SI) expressed as the ratio [IC50 L6-cells / IC50 T.b. rhodesiense] 
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Table 5. Structure, in vitro trypanocidal activity and cytotoxicity of diphenyl 
derivatives 27a-41b. 
X
R R
 
 
Entry 
 
Compd R 
 
 
X 
 
T. brucei  
rhodesiense 
IC50 (µM)a 
Cytotoxicity 
L6-cells 
IC50 (µM) 
Selectivityb 
 
1 27a CH2 11.6 - - 
2 28a NH 0.048 9.8 202 
3 29a CO 7.2 - - 
4 30a 
BocN
N
BocN
 
SO2 2.6 56.4 21.7 
5 27b CH2 0.897 63.6 71 
6 28b NH 0.069 212 3072 
7 29b CO 2.05 >214 > 104 
8 30b 
N
N
HNH
 
SO2 32.4 - - 
9 31a CH2 31.7 - - 
10 32a NH 0.470 3.7 7.9 
11 33a 
NBoc
NHBocN
H
 
SO2 24.4 - - 
12 31b CH2 0.161 2.8 17.4 
13 32b NH 0.022 0.65 29.5 
14 33b SO2 4.3 >222 > 51 
15 34 
NH
NH2N
H
 
CO 0.206 2.7 13.1 
16 31c CH2 0.316 >175 > 554 
17 32c NH
N
HNH
EtO
OEt
 
NH 0.228 
 
>175 
 
> 767 
 
18 35 N
N
HNH
 
NH 1.4 
 
113 
 
80.7 
 
19 36 Br CO 25.9 >244 > 9.4 
20 37 P+(n-C5H11)3 CO 0.414 11.8 28.5 
21 38 NO2 41.8 - - 
22 39 NH2 1.42 >217 > 152 
23 40a NBoc
NHBocN
H
 
13.8 
 
- 
 
- 
 
24 40b NH
NH2N
H
 
0.270 
 
46.4 
 
172 
 
25 41b N
N
HNH
 
 
 
N N
 
0.118 
 
104 
 
881 
 
a Controls: melarsoprol IC50 = 5.5 nM (SI= 3456); diminazene diaceturate IC50= 8.9 nM; 
CGP40215 IC50 = 4.5 nM [ref 43]. 
b Selectivity index (SI) expressed as the ratio [IC50 L6-cells / 
IC50 T.b. rhodesiense] 
 
 
